Reducing hyperglucagonaemia in type 2 diabetes using low-dose glibenclamide: Results of the LEGEND-A pilot study

Diabetes Obes Metab. 2022 Aug;24(8):1671-1675. doi: 10.1111/dom.14740. Epub 2022 May 18.
No abstract available

Keywords: antidiabetic drug; clinical trial; drug mechanism; experimental pharmacology; glucagon; type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon
  • Glyburide / therapeutic use
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin
  • Pilot Projects

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Glucagon
  • Glyburide

Associated data

  • ClinicalTrials.gov/NCT02830048